Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inolimomab vs usual care in primary steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation
2007-005009-24Phase 3Completed
- Sponsor
- EUSA Pharma
- Start
- Mar 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of inolimomab in Acute Graft-Versus-Host Disease (aGvHD) and graft-versus-host disease (GVHD) (2 arms), sponsored by EUSA Pharma. Primary endpoint: Therapy success at 1 year. Started Mar 2008; status: completed.
02
Drugs
inolimomab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2007-005009-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005009-24.